PNB Vesper has received permission from the Drugs Controller General of India (DCGI) to enter into the phase-III clinical trials of PNB 001/GPP-BALACOVIN, the company said in a statement.
PNB Vesper, a leading Kerala-based life sciences company received permission from the DCGI and entering into the final phase 3 clinical trials. After a detailed deliberation by the Subject Expert Committee (SEC) on the phase 2 clinical trial results of PNB001 (GPP-Balacovin), the company has now been given a green signal to conduct a nationwide multi-centered phase 3 clinical trial on hospitalized Covid-19 patients with oxygen support.